The National Cancer Institute's Structure Biophysics Lab seeks partners interested in licensing or co-developing a technology to site-specifically label RNA.
The National Cancer Institute seeks parties interested in co-development of safe and effective TEM5 agonists and/or antagonists that modulate WNT signaling.
Researchers at the National Cancer Institute (NCI) seek licensing for an improved cell line called Tni-FNL which is capable of high level expression of heterologous proteins using baculovirus expression systems.
